Recent Updates
Recently added Catalysts

GSK561679

Phase 2

Depressive Disorder, Major | Small molecule | Psychiatry |GSK plc|Trials Updated: Jan 31, 2018

GSK561679 development status

Highest phase Phase 2
Registered trials 19 across 6 sponsors since Oct 2005

GSK561679 target and mechanism

ModalitySmall molecule

Also known as GSK561679 tablet, GSK561679 tablet or solution, alprazolam, GW876008

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials6
Total Enrollment652

FDA Designations

No designations recorded

GSK561679 clinical trials

GSK561679 · 6 trials · 4 indications

Phase 2 4Phase 1 2
NCT00733980A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive DisorderDepressive Disorder, Major
COMPLETED150 Analytics
NCT00385099Effects Of GW876008 On The Bowel In Patients With Irritable Bowel SyndromeIrritable Colon
COMPLETED10 Analytics
NCT00397722Treatment Of Patients With Social Anxiety DisorderSocial Phobia
COMPLETED299 Analytics
NCT00421707Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel SyndromeIrritable Bowel Syndrome (IBS)
COMPLETED133 Analytics
PHASE2COMPLETED
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
Depressive Disorder, MajorUnlock trial analytics
PHASE2COMPLETED
Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome
Irritable ColonUnlock trial analytics
PHASE2COMPLETED
Treatment Of Patients With Social Anxiety Disorder
Social PhobiaUnlock trial analytics
PHASE2COMPLETED
Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome
Irritable Bowel Syndrome (IBS)Unlock trial analytics

Study Endpoints

Primary Endpoints

Change From Randomization to the End of Treatment Phase (Week 6) in the Bech Melancholia Subscale (Bech) (Items 1, 2, 7, 8, 10 and 13) From the Hamilton Rating Scale for Depression (HamD17).
Randomization (Week 0) and Week 6

The Bech Melancholia Sub-scale is extracted from the HAMD-17 and is comprised of the following 6 items: Depressed Mood, Feelings of Guilt, Work and Activities, Retardation, Anxiety Psychic, and Somatic Symptoms General. The items Depressed Mood, Feelings of Guilt, Work and Activities, Retardation, Anxiety Psychic are scored on a 5-point scale from 0 to 4 except for Somatic Symptoms General which is scored on a 3-point scale from 0 to 2 where the higher scores reflecting greater severity. The Bech Melancholia Scale total score is calculated by summing the individual response scores. The highest possible score is 22 (indicative of greater severity) and the lowest possible score is 0 (indicating absence of symptoms). Change from randomization was defined as the post-baseline value minus the value at randomization. Randomization was defined as Week 0.

Percent change from Baseline in Laser Doppler regional Rectal Mucosal Blood Flow (RMBF) measured in response to physiological stress (cold water pressor test)
Baseline (pre-dose) and Study Days 1, 2 and 3

Laser Doppler flowmetry measures changes in red cell flux using a probe that scans a fixed volume of tissue. Participants were examined in the left lateral position where DRT4 laser Doppler flow meter was placed against the rectal mucosa 10 centimeter (cm) above the lower limit of the anal margin, and pre-stress readings were taken after a period of 10 minutes of acclimatization in a room with an ambient temperature of 22 degrees Celsius. Physiological stress was evoked using the cold water pressor test. Participants were asked to place their hand and forearm into a container of ice-cold water at 0-4degree Celsius and were persuaded to maintain that position for as long as possible during the stress period of 10 minutes. Readings were then taken during pre-stress and at 5-minute intervals during the stress and recovery periods. Baseline was defined as the pre-dose assessment. Change from Baseline was calculated by subtracting the Baseline value minus the post-randomization value.

Percent Change from Baseline in Laser Doppler regional RMBF measured in response to psychological stress (dichotomous listening test)
Baseline (pre-dose) and Study Days 1, 2 and 3

Laser Doppler flowmetry measures changes in red cell flux using a probe that scans a fixed volume of tissue, an indirect measure of flow can be obtained. Participants were examined in the left lateral position with no prior bowel preparation. The laser Doppler probe (DRT4 laser Doppler flow meter) was then placed against the rectal mucosa 10 centimeter above the lower limit of the anal margin, and pre-stress readings were taken after a period of 10 minutes of acclimatization in a room with an ambient temperature of 22 degrees Celsius. The dichotomous listening test was used as a psychological stressor. At the onset of stress, folk music was played into one ear and rock music into the other ear for 10 minutes. Readings were then taken during pre-stress and at 5-minute intervals during the stress and recovery periods. Baseline was defined as the pre-dose assessment. Change from Baseline was calculated by subtracting the Baseline value minus the post-randomization value.

Change from randomization in the clinician-administered LSAS total score at the end of the treatment phase (Week 12)
Baseline (Day 0) and Week 12

The LSAS is an investigator-rated scale consisting of 48 questions concerning various social situations. The LSAS is the first psychiatric assessment at all post-screening visits. A qualified independent efficacy rater scored the participant's "fear or anxiety" and "avoidance" of social situations on 4-point scale : where, 0= None, 1= Mild, 2= Moderate, 3= Severe. Scores were recorded in participant's source documents. The LSAS total score was the sum of each of the forty-eight individual responses. Day 0 was Baseline and change from Baseline was calculated by subtracting Baseline value from Week 12 value. Data for adjusted mean and SE is presented.

Change from randomization on the LSAS Fear subscale score at Week 12
Baseline (Day 0) Week 12

The LSAS consisted of 24 fear responses. All individual items were rated on a scale 0 (none) -3 (severe) with higher scores indicating more severe fear. The LSAS fear subscale score was the sum of each of the 24 individual responses. If at least 22 items of the items making up the subscale of interest were present at a particular time point, the subscale score was calculated as Sum of non-missing items multiplied with 24/Number of non-missing items. If less than 22 of the items making up the score of interest were available for a participant at a particular time point, the subscale score was not calculated for that time point. Day 0 was Baseline and change from Baseline was calculated by subtracting Baseline value from Week 12 value. Data for adjusted mean and SE is presented.

Change from randomization on the LSAS Avoidance subscale score at Week 12
Baseline (Day 0) and Week 12

The LSAS consisted of 24 avoidance responses. All individual items were rated on a scale 0 (never) -3 (always) with higher scores indicating more severe avoidance. The LSAS avoidance subscale Score was the sum of each of the 24 individual responses. If at least 22 items of the items making up the subscale of interest were present at a particular time point, the total score was calculated as Sum of non-missing items multiplied with 24/Number of non-missing items. If less than 22 of the items making up the score of interest were available for a participant at a particular time point, the subscale score was not calculated for that time point. . Day 0 was Baseline and change from Baseline was calculated by subtracting Baseline value from Week 12 value. Data for adjusted mean and SE is presented.

Change from randomization on the Social Avoidance and Distress Scale (SADS) total score at Week 12
Baseline (Day 0) and Week 12

The SADS is a 28 item questionnaire. The total score was obtained by summing together the responses for all 28 items from the SADS questionnaire. Each individual item was rated as true or false. One point was given where items 2, 5, 8, 10, 11, 13, 14, 16, 18, 20, 21, 23, 24, 26 were marked as true and 1 point when each of the remaining items were marked as false. This gave a possible range of possible scores from 0 to 28 with higher scores indicating more severe disorder. If at least 26 of the items making up the total score were present at a particular time point, the total score was calculated as Sum of scores for non-missing items multiplied with 28/Number of non-missing items. If less than 26 of the items making up the score of interest were available for a participant at a particular time point, the total score was not calculated for that time point.

Number of Participants With Average Adequate Relief Rate During the Last 4 Weeks of the Treatment Periods (Weeks 3-6. in Period 1, Weeks 12-15 in Period 2).
Up to Day 105 (weeks 3-6. in period 1, weeks 12-15 in period 2)

For the assessment of average adequate relief rate from IBS symptoms for a participant was planned by collecting the response of a question 'In the past seven days have you had adequate relief of your IBS pain or discomfort? However, in error, the question was not collected in the IVRS system. Therefore, data for this endpoints was not collected during this study.

Number of Participants With Changes in Weekly Adequate Relief Rates During the Treatment Periods (Weeks 1-6 in Period 1 and Weeks 9-15 in Period 2).
Up to Day 105 (weeks 1-6 in period 1 and weeks 9-15 in period 2).

For the assessment of changes in weekly adequate relief rates during the treatment periods was planned by collecting the response of a question. Overall response was defined as having achieved adequate relief in last 4 weeks. However, in error, the question was not collected in the IVRS system. Therefore, data for this endpoints was not collected during this study.

Number of Participants With Adequate Relief of IBS Pain and Discomfort on All 4 of the Last 4 Weeks of the Treatment Phase Treatment Periods 1 and 2
Up to Day 105

For the assessment of average adequate relief rate from IBS symptoms for a participant was planned by collecting the response of a question whether weekly adequate relief from IBS symptoms was achieved?. However, in error, the question was not collected in the IVRS system. Therefore, data for this endpoints was not collected during this study.

Mean Global Improvement Scale (GIS) Responder Rate Over the Last Four Weeks by Regimen
Up to Day 105 (weeks 3-6 in period 1, weeks 12-15 in period 2)

The GIS is comprised of ten questions, all rated on a seven point scale ranging from substantially worse (7) to substantially improved (1). GIS assesses the participant's improvement (or worsening) as assessed by the clinician on a 7-point scale: 1: very much improved; 2: much improved; 3: minimally improved; 4: no change; 5: minimally worse; 6: much worse; or 7: very much worse for diarrhea, constipation, stool frequency, stool consistency, urgency, bloating, incomplete evacuation, and straining. Values reported are less than the minimum score on scale as the rate is the proportion of the last four weeks that the participant is a responder.

Ratings on Irritable Bowel Syndrome Quality of Life (IBSQoL) Scale
Up to Day 105 (weeks 3-6 in period 1, weeks 12-15 in period 2)

The IBSQoL is a self-report quality-of-life measure specific to IBS that can be used to assess the impact of IBS and its treatment. The IBSQoL consists of 30 statements about bowel problems, which formed 9 scales: emotional health, mental health, health belief, sleep, energy, physical functioning, diet, social role, physical role and sexual relation. All 9 scales were rated on a five-point response scale ranging from 1 (always) to 5 (never). Scores for individual items were averaged to obtain a total score for each subscale of IBSQoL. Then transformed to a 0-100 scale for ease of interpretation with higher scores indicating better IBS-specific quality of life. Transformed scale score = (raw score - lowest possible scale score)/ (scale range) X 100. The data presented for individual scale.

Changes of fMRI activation in amygdala of subjects with SAD during an emotional task after having received different compounds. Change in the VAS score in response to Public Speaking stress after having received different compounds.
over 6 weeks
Signal reductions in the amygdala during viewing of emotional faces and during abdominal pain threat as measured by the fMRI.
throughout the study

Secondary Endpoints

Change From Randomization to Weeks 1, 2, and 4 in the Bech Melancholia Scale Score.
Randomization (Week 0) and Week 1, 2 and 4
Change From Randomization to Weeks 1, 2, 4, and 6 in the Hamilton Anxiety Scale (HAM A)
Randomization (Week 0) and Week 1, 2, 4 and Week 6
Change From Randomization to Weeks 1, 2, 3, 4, and 6 in the Inventory of Depressive Symptomatology-Self- Report (IDS-SR) Total Score.
Randomization (Week 0) and Week 1, 2, 3,4 and Week 6
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
GSK561679 armEXPERIMENTALDouble blind GSK561679
placebo armPLACEBO_COMPARATORDouble blind placebo
GW876008EXPERIMENTALGW876008
PlaceboPLACEBO_COMPARATORPlacebo
GSK561679EXPERIMENTALThe subjects will be randomized to one of the six sequences A/C/D A/D/C C/A/D C/D/A D/A/C D/C/A across three treatment periods where A represents placebo, C represents GSK561679 and D represents alprazolam.
GW876008 20mcgEXPERIMENTALGW876008 20mcg
GW876008 200mcgEXPERIMENTALGW876008 200mcg

Interventions

NameTypeDescription
GSK561679DRUGGSK561679
PlaceboOTHERPlacebo
GW876008DRUG -
paroxetineDRUG -
GSK561679 tabletDRUGGSK561679 tablets are white film-coated tablets, containing 200 (milligrams) mg of the free base, GSK561679A.
GW876008 tabletDRUGGW876008 tablets are white to off-white round film-coated tablets, containing 100 mg of GW876008X (free base).
alprazolamDRUGAlprazolam capsules 0.25 mg are hard gelatine capsules containing 1 tablet of commercial alprazolam (Xanax 0.25).
GW876008 200mcgDRUGGW876008
GW876008 20mcgDRUGGW876008 20mcg
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 64 Years
SexFEMALE
Healthy VolunteersNo
Study Sites18

Inclusion criteria: * Female outpatients aged 25-64 years, inclusive. * Subjects must have the ability to comprehend the consent form, and provide informed consent. * Subject currently meets the diagnosis for MDD (without psychotic features), single episode or recurrent, as defined in the DSM-IV-TR...

Countries:United StatesUnited KingdomCanadaFinlandGermanyNorwaySouth AfricaSwedenSpain
Unlock Eligibility Criteria

Frequently asked questions about GSK561679

What is GSK561679?

GSK561679 is an investigational small molecule developed by GSK plc (ticker GSK) for psychiatric conditions. It has been studied in major depressive disorder and social phobia. It is a tablet or solution formulation and remains in clinical development rather than being an approved medicine.

What is GSK561679 used for?

GSK561679 has been studied for major depressive disorder and social phobia. The Phase 2 trial enrolled women with major depressive disorder, while an earlier Phase 1 study evaluated a potential anxiolytic effect in subjects with social anxiety disorder. It is not an approved treatment for either condition.

Who makes GSK561679?

GSK561679 is developed by GSK plc, which trades under the ticker GSK. The company sponsored the clinical studies of the compound in major depressive disorder and social phobia.

What phase is GSK561679 in?

GSK561679 has reached Phase 2. The Phase 2 study in women with major depressive disorder is completed, and a Phase 1 study in social anxiety disorder is also completed. The compound is investigational and has not been approved for any indication.

What clinical trials is GSK561679 in?

GSK561679 has been evaluated in two completed trials. NCT00733980 was a Phase 2 study of GSK561679 in females with major depressive disorder, enrolling 150 participants in the United States. NCT00555139 was a Phase 1 study comparing anxiolytic effects in subjects with social anxiety disorder, enrolling 35 participants in Spain.

Is GSK561679 the same as GSK561679 tablet or GSK561679 tablet or solution?

Yes. GSK561679 tablet and GSK561679 tablet or solution are alternative names for the same investigational compound, GSK561679. These names refer to the tablet and solution formulations of the drug developed by GSK plc.